

## Lyka Labs announces FY16 Financial Results

### FY16 Revenues at INR 130.66 Crores EBIDTA at INR 22.26 Crores

**Mumbai, 27<sup>th</sup> May, 2016:** Lyka Labs Limited, a pharmaceutical company with business across 46 countries globally in super specialty segments of Injections and Dermatology today announced its Financial Results for the Financial Year ended 31<sup>st</sup> March 2016.

## Financial Results

### FY16\* (Year Ended 31<sup>st</sup> March 2016) – Standalone

- Revenue was at **INR 57.26 Crores**
- EBIDTA Margin at **33.47% (INR 19.17 Crores)** compared to **22.14% (INR 20.03 Crores)** in FY15\*
- Finance Cost was **down at INR 11.44 Crores** compared to **INR 18.34 Crores** in FY15\*
- Net Profit was up at **INR 4.82 Crores** compared to **INR 1.37 Crores** in FY15\*

*\*FY16 was a 9 Month Financial Year and FY15 was a 12 Month Financial Year. The change in accounting year of FY16 is done to comply with the Company Law Board Requirements.*

### FY16\* (Year Ended 31<sup>st</sup> March 2016) – Consolidated

- Revenue was at INR 130.66 Crores
- EBIDTA Margin at 17.32% compared to 17.86% in FY15
- Finance Cost was **down at INR 15.18 Crores** compared to **INR 24.16 Crores** in FY15
- Net Profit was up at **INR 3.69 Crores** compared to **loss of INR 4.94 Crores** in FY15
- Net Profit factors one-time write-offs of Bad Debts of INR 6.72 Crores

*\*The Financial Year for Lyka Labs is for 9 Months whereas for all Subsidiaries is 12 Months. The above figures include 9 Month Data for Lyka Labs and 12 Month Data for all the Subsidiaries.*

## Business Review and Strategy

- Proposed Merger of Subsidiaries (Lyka Exports Limited and Lyka Healthcare Limited) with Lyka Labs
- Consolidated Revenues grew 11.22% over Quarter Ended December 2015.
- Exports Business grew 33% over quarter ended December 2015
- Received 42 Product Approvals in FY16 and expect 68 Product Approvals in FY17 for ROW Markets
- 150 Product Filling planned in FY17 for ROW Markets
- Domestic Marketing Business grew 11% over FY15
- Launched 2 New Marketing Division in India
  - Cerabelle (Dermatology and Cosmetology Products)
  - Enspan (Critical Care and Anesthesia Products)
- Focus on Research for NDDS in Injections and Topical Preparations
- Commercialization of R&D by licensing products in leading domestic and international pharmaceutical companies
- Enhancement of Production Capacity at Ankleshwar Facility.

## About Lyka Labs Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20+ Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

### For Queries, Please Contact

#### **Lyka Labs Limited**

##### **Yogesh Shah**

Chief Financial Officer

Tel: +91 22 66112200

[ybshah@lykalabs.com](mailto:ybshah@lykalabs.com)

##### **Piyush Hindia**

Company Secretary

Tel: +91 22 66112200

[companysecretary@lykalabs.com](mailto:companysecretary@lykalabs.com)

##### **Registered Office**

Lyka Labs Limited

4801/B & 4802/A

G.I.D.C. Industrial Estate,

Ankleshwar – 393 002

##### **Corporate Information**

**BSE Code:** 500259

**NSE Code:** LYKALABS

**Website:** [www.lykalabs.com](http://www.lykalabs.com)

**CIN:** L24230GJ1976PLC008738

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances